BofA Securities has upgraded Globus Medical (NYSE:GMED) to neutral from underperform, citing the company's strong Q4 revenue ...
A.M. Eastern Time on Tuesday, Jan. 28, 2025, to discuss the company's fourth quarter and full-year 2024 financial results.
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis ("UC”) reaches 1,003 of 1,224 ...
Investors are watching to see if technology companies and related heavyweights will add to recent strong profit gains and ...